Continuous theta-burst stimulation to a lesion network in cervical dystonia: a randomized, double-blind, sham-controlled, pilot trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The mechanisms driving cervical dystonia remain unclear, limiting effective, non-invasive treatment development. Lesion network mapping previously localized a brain network derived from lesions causing cervical dystonia, with a network hub in the somatosensory cortex, a viable target for non-invasive brain stimulation.
Objectives
We conducted a randomized, sham-controlled, crossover trial administering continuous theta-burst stimulation (cTBS) to the S1 lesion network hub, testing whether modulating this network reduces CD symptoms.
Methods
Thirteen idiopathic cervical dystonia patients (57.85 ± 10.85 years) received two 10-session blocks of bilateral somatosensory cortex cTBS (active or sham; counterbalanced). The primary outcome was change in cervical dystonia symptoms, measured by the Toronto Western Spasmodic Torticollis Scale (TWSTRS). A wearable motion sensor objectively measured change in head and neck movement patterns. Motor evoked potentials and resting-state fMRI assessed cTBS-induced changes in corticospinal excitability and functional connectivity, respectively.
Results
Active cTBS did not significantly reduce cervical dystonia symptoms compared to sham (condition × timepoint interaction: p = .149). Range of motion significantly increased with active, versus sham, cTBS ( p = .015). Corticospinal excitability decreased following sham ( p = .042), but not active, cTBS. No significant connectivity changes were seen from the somatosensory cortex stimulation site after active cTBS; however, significant changes emerged from the globus pallidus interna.
Conclusion
This study prospectively tested the effects of neuromodulation on a lesion network mapping-derived target. Active cTBS did not significantly improve TWSTRS scores relative to sham. The intervention was well tolerated by all patients, and future studies could consider higher-dose or alternative protocols to this target.
